Depolarizing γ-aminobutyric acid contributes to glutamatergic network rewiring in epilepsy

Ann Neurol. 2017 Feb;81(2):251-265. doi: 10.1002/ana.24870.

Abstract

Objective: Rewiring of excitatory glutamatergic neuronal circuits is a major abnormality in epilepsy. Besides the rewiring of excitatory circuits, an abnormal depolarizing γ-aminobutyric acidergic (GABAergic) drive has been hypothesized to participate in the epileptogenic processes. However, a remaining clinically relevant question is whether early post-status epilepticus (SE) evoked chloride dysregulation is important for the remodeling of aberrant glutamatergic neuronal circuits.

Methods: Osmotic minipumps were used to infuse intracerebrally a specific inhibitor of depolarizing GABAergic transmission as well as a functionally blocking antibody toward the pan-neurotrophin receptor p75 (p75NTR ). The compounds were infused between 2 and 5 days after pilocarpine-induced SE. Immunohistochemistry for NKCC1, KCC2, and ectopic recurrent mossy fiber (rMF) sprouting as well as telemetric electroencephalographic and electrophysiological recordings were performed at day 5 and 2 months post-SE.

Results: Blockade of NKCC1 after SE with the specific inhibitor bumetanide restored NKCC1 and KCC2 expression, normalized chloride homeostasis, and significantly reduced the glutamatergic rMF sprouting within the dentate gyrus. This mechanism partially involves p75NTR signaling, as bumetanide application reduced SE-induced p75NTR expression and functional blockade of p75NTR decreased rMF sprouting. The early transient (3 days) post-SE infusion of bumetanide reduced rMF sprouting and recurrent seizures in the chronic epileptic phase.

Interpretation: Our findings show that early post-SE abnormal depolarizing GABA and p75NTR signaling fosters a long-lasting rearrangement of glutamatergic network that contributes to the epileptogenic process. This finding defines promising and novel targets to constrain reactive glutamatergic network rewiring in adult epilepsy. Ann Neurol 2017;81:251-265.

MeSH terms

  • Animals
  • Bumetanide / administration & dosage
  • Bumetanide / pharmacology*
  • K Cl- Cotransporters
  • Male
  • Mossy Fibers, Hippocampal / drug effects*
  • Nerve Tissue Proteins
  • Rats
  • Rats, Wistar
  • Receptors, Growth Factor
  • Receptors, Nerve Growth Factor / drug effects*
  • Signal Transduction / drug effects*
  • Sodium Potassium Chloride Symporter Inhibitors / administration & dosage
  • Sodium Potassium Chloride Symporter Inhibitors / pharmacology*
  • Solute Carrier Family 12, Member 2 / drug effects*
  • Status Epilepticus / drug therapy
  • Status Epilepticus / metabolism*
  • Status Epilepticus / physiopathology
  • Symporters / drug effects*
  • gamma-Aminobutyric Acid / drug effects*

Substances

  • Nerve Tissue Proteins
  • Receptors, Growth Factor
  • Receptors, Nerve Growth Factor
  • Slc12a2 protein, rat
  • Sodium Potassium Chloride Symporter Inhibitors
  • Solute Carrier Family 12, Member 2
  • Symporters
  • Bumetanide
  • Ngfr protein, rat
  • gamma-Aminobutyric Acid